XBIT XBiotech: Earnings per share for the trailing year

Public company logo of XBiotech Inc (XBIT)

XBiotech Inc. (XBIT) develops human antibodies to combat tumors, protecting its innovations with patent barriers. The therapy's effectiveness relies on strict medical oversight during the transport of drugs to clinics. Serving as the primary valuation tool, this chart on GURU.Markets reflects an EPS of -50.20. The company is currently scaling its portfolio of immune solutions in an effort to attract major strategic allies.

XBiotech Inc (XBIT): Net earnings per share for the last 12 months from 02/11/2024 to 11/15/2026

XBiotech Inc - analytical breakdowns and key metrics (XBIT)

- current quotes and average value forecast:
Stock Price XBiotech|XBIT - Price Target Chart
- company stock capitalization data:
Market Value XBiotech USA|XBIT - Enterprise Value
- issuer book value statistics:
Net Asset Value per Share XBiotech|XBIT - Company Net Assets|Capitalization to Book Value Ratio xbiotech.com|XBIT - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity XBiotech Inc.|XBIT - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient XBiotech|XBIT - Company Debts|Debts to Book Value XBiotech|XBIT - Company Long-Term Liabilities|Amount of Current Liabilities XBiotech|Immediate Liquidity xbiotech.com
- net income and valuation ratios data:
XBIT - Net Profit|Future Profit XBiotech Inc.|XBIT - P/E Multiple|Future Price to Earnings Multiple XBiotech Inc|XBIT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation XBiotech USA|XBIT - Operating profit EBITDA|Net earnings per share for the last four quarters XBiotech|XBIT - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months xbiotech.com|XBIT - Earnings growth in current year|Expected earnings per share growth for next year XBiotech Inc.
- sales volume and revenue information:
XBIT - Company Sales|Company Future Sales XBiotech Inc|XBIT - Market Cap to Revenue|Market Cap to Projected Revenue XBiotech USA|XBIT - Sales Growth YoY (TTM)
Initial company analysis:XBIT, XBiotech Inc.
Flagship merchandise of XBiotech

For XBiotech Inc. (XBIT), the dependence on the success of a narrow portfolio of oncology antibodies makes the 12-month EPS growth rate a critical indicator of financial stability. This metric measures the percentage change in net income per share over a trailing twelve-month (TTM) period, allowing investors to promptly assess the impact of patent risks and operational shocks on the actual return on equity.

Direct competitors

Earnings per share for the trailing year ONC (BeiGene)|Halozyme Inc. (HALO) - Earnings per share for the last twelve months|RevMed - Earnings per share for the trailing year|AAPG (Ascentage Pharma Group International) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CG Oncology, Inc. CGON|Net earnings per share for the last 12 months URGN (urogen.com)|Earnings per share for the last twelve months BCAX (Bicara Therapeutics)|Net earnings per share (EPS TTM) PSNL (personalis.com)|Earnings per share for the trailing year ERAS|DCTH - Earnings per share for the last twelve months|Y-mAbs Therapeutics (YMAB) - Net earnings per share for the last 12 months|AURA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months CADL|Earnings per share for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ACTU (Actuate Therapeutics, Inc)|Net earnings per share for the last four quarters Citius Oncology|TuHURA Biosciences, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Protara TARA|fatetherapeutics.com - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aadi Bioscience|TCRX: Net earnings per share (EPS TTM)|CSBR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months cel-sci.com|OS Therapies (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Adlai Nortye Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year VERU|tempesttx.com - Net earnings per share (EPS TTM)|XLO - Net earnings per share (EPS TTM)|Enochian BioSciences (RENB) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Mural Oncology plc (MURA)|Earnings per share for the last twelve months Kairos Pharma Ltd|Net earnings per share (EPS TTM) OnKure Therapeutics|Net earnings per share for the last 12 months GDTC (w2.cytomed.sg)|Net earnings per share (EPS TTM) Curis Inc. (CRIS)|Earnings per share for the last twelve months Apollomics Inc. APLM|Earnings per share for the trailing year THAR|ADVB - Earnings per share for the last twelve months|GNPX - Net earnings per share (EPS TTM)|CLDI (calidibio.com) - Net earnings per share for the last 12 months|SBFM - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months XBIO|Salarius (SLRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Purple Biotech Ltd. (PPBT)|Earnings per share for the last four quarters AONC|Earnings per share for the last twelve months BeiGene BGNE|CKPT - Net earnings per share for the last 12 months|elevationoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ICAD (icadmed.com)|IKNA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NTBL|VIRX (viracta.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months MorphoSys Inc MOR|Earnings per share for the last twelve months NAYA Bio (NAYA)|AAPGV: Earnings per one share for the last 12 months